Details of Disease

General Information of Disease (ID: DISQ8RM8)

Disease Name Migraine
Synonyms
Mgr1; migraine; Mgau; migraine, susceptibility to; migraine with or without aura, susceptibility to, type 1; migraine without aura, susceptibility to; migraine with or without aura, susceptibility to, 1; migraine, resistance to
Disease Class 8A80: Migraine
Disease Hierarchy
DISHW5IK: Migraine with or without aura, susceptibility to
DISQ8RM8: Migraine
ICD Code
ICD-11
ICD-11: 8A80
ICD-10
ICD-10: G43, G43.9
ICD-9
ICD-9: 346
Expand ICD-9
346
Disease Identifiers
MONDO ID
MONDO_0008000
MESH ID
D008881
UMLS CUI
C3887485
OMIM ID
157300
MedGen ID
854348
HPO ID
HP:0002076
SNOMED CT ID
37796009

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 25 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Almogran DM7I64Z Approved Small molecular drug [1]
Amfepramone DM9YSNQ Approved Small molecular drug [2]
Atogepant DMZGKXW Approved NA [3]
Budipine DMODHQI Approved Small molecular drug [4]
Buprenorphine DMPRI8G Approved Small molecular drug [5]
Dihydroergotamine DM5IKUF Approved Small molecular drug [6]
Eletriptan DMW649X Approved Small molecular drug [7]
Eptinezumab DM5LJCI Approved NA [8]
Flunarizine DMZU5JP Approved Small molecular drug [9]
Frovatriptan DM7RE8P Approved Small molecular drug [10]
Ketoprofen DMRKXPT Approved Small molecular drug [11]
Lasmiditan DMXLVDT Approved Small molecular drug [12]
LOMERIZINE DME0TC8 Approved Small molecular drug [13]
Lornoxicam DMYZFXN Approved Small molecular drug [13]
Methysergide DM1EF73 Approved Small molecular drug [14]
Naratriptan DMO50U2 Approved Small molecular drug [15]
Propranolol DM79NTF Approved Small molecular drug [16]
Rimegepant DMHOAUG Approved Small molecular drug [17]
Rizatriptan DMDJMA3 Approved Small molecular drug [18]
Sumatriptan DMVYXR8 Approved Small molecular drug [19]
Treximet DMU54QB Approved Small molecular drug [20]
Ubrogepant DM749I3 Approved Small molecular drug [21]
Zavegepant DMTROUI Approved Small molecular drug [22]
Zolmitriptan DM1IB4Q Approved Small molecular drug [23]
LY2951742 DMP96JO Phase 4 NA [24]
------------------------------------------------------------------------------------
⏷ Show the Full List of 25 Drug(s)
This Disease is Treated as An Indication in 29 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
DFN-02 DM8FZAB Phase 3 NA [11]
DFN-15 DM3BF9B Phase 3 NA [11]
M207 DM2CLXU Phase 3 NA [11]
PH80-PMD DMUJORY Phase 3 NA [25]
Recombinant botulinum neurotoxin vaccine DM8I4HO Phase 3 NA [26]
TEV-48125 DMMTKC6 Phase 3 Antibody [27]
AGS-003 DMMNLWI Phase 2 NA [28]
ALD-403 DM6RBYT Phase 2 NA [29]
ALLOD-2 DMCITS3 Phase 2 NA [11]
AMG 301 DMO72IF Phase 2 NA [11]
AMG 334 DMI3WFG Phase 2 NA [30]
BGC-20-1531 DMS2MQ5 Phase 2 Small molecular drug [31]
BI-44370 DMZR9OU Phase 2 NA [32]
Dorolac DMVWZDB Phase 2 NA [11]
LY-2590443 DM81UJW Phase 2 NA [33]
LY-334370 DM43O9N Phase 2 Small molecular drug [34]
MK-3207 DM6OLGC Phase 2 Small molecular drug [35]
NXN-188 DMMBAIH Phase 2 Small molecular drug [36]
Olcegepant DMVW5KR Phase 2 Small molecular drug [37]
SB-705498 DMRYHWI Phase 2 Small molecular drug [38]
Telcagepant DMFT5D6 Phase 2 Small molecular drug [39]
AMG 333 DMF9VNC Phase 1 NA [40]
BF-1 DM7RPSG Phase 1 Small molecular drug [41]
CVT-427 DMPYUWH Phase 1 NA [11]
INP104 DMVKPD8 Phase 1 NA [11]
LBR-101 DM4YA0D Phase 1 Antibody [42]
PF-4427429 DM3427C Phase 1 NA [43]
TRV250 DM2WZ86 Phase 1 NA [11]
XEN007 DMNKV3O Phase 1 NA [44]
------------------------------------------------------------------------------------
⏷ Show the Full List of 29 Drug(s)
This Disease is Treated as An Indication in 25 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Alniditan DMFE3CT Discontinued in Phase 3 Small molecular drug [45]
Avitriptan DM3SE2N Discontinued in Phase 3 Small molecular drug [46]
LLL-2011 DM5EQID Discontinued in Phase 3 NA [47]
4991W93 DMUXMGN Discontinued in Phase 2 Small molecular drug [48]
CP-122288 DM3OJP0 Discontinued in Phase 2 Small molecular drug [49]
FK-888 DM457B1 Discontinued in Phase 2 Small molecular drug [50]
GV-196771 DMFN21T Discontinued in Phase 2 Small molecular drug [51]
IS-159 DMLQWFA Discontinued in Phase 2 Small molecular drug [52]
LY-2300559 DMTS1X5 Discontinued in Phase 2 NA [53]
PNU-142633 DMLK5IM Discontinued in Phase 2 Small molecular drug [54]
SERGOLEXOLE MALEATE DM9KB8A Discontinued in Phase 2 Small molecular drug [55]
ALX-0646 DMNOZAI Discontinued in Phase 1 Small molecular drug [56]
GR-127607 DMRNI6K Discontinued in Phase 1 NA [57]
MT-500 DMCJ1B2 Discontinued in Phase 1 Small molecular drug [58]
Tidembersat DMTC4LP Discontinued in Phase 1 Small molecular drug [59]
ALX-0625 DM4PK3X Terminated NA [63]
BMS-181885 DMYWI04 Terminated NA [64]
Dotarizine DM6Q05K Terminated Small molecular drug [65]
L-694247 DM2F4GT Terminated Small molecular drug [66]
LY467711 DM0TV9L Terminated Small molecular drug [67]
LY525327 DMPNMAR Terminated Small molecular drug [67]
OX-641 DMP0F6O Terminated NA [68]
PNU-109291 DMZNM2K Terminated Small molecular drug [69]
SRSS-023 DMUGPDB Terminated NA [70]
VR-147 DMLWQOP Terminated NA [71]
------------------------------------------------------------------------------------
⏷ Show the Full List of 25 Drug(s)
This Disease is Treated as An Indication in 5 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Rizaport DMG59CZ Application submitted NA [11]
Semprana DMBWI67 Application submitted NA [11]
BIO-306 DMPUBK8 Preclinical Small molecular drug [60]
Donitriptan DMA2K7C Preclinical Small molecular drug [61]
XP-20925 DMFNXNO Preclinical NA [62]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 8 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
ALGRX 2872 DM9Y5M5 Investigative NA [72]
BMS-694153 DM8PA3U Investigative Small molecular drug [73]
CL-H01 DM74LLK Investigative NA [72]
CWF-0902 DMEBZIG Investigative NA [72]
ELS-110 DM8VKU0 Investigative NA [72]
MK-2918 DMDB1IQ Investigative NA [72]
MystiTrip DMVBSBF Investigative NA [72]
XGP-310 DMTG604 Investigative NA [72]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 1 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ALPK1 OTBW6SGD Strong Genetic Variation [74]
------------------------------------------------------------------------------------

References

1 Drug information of Almogran, 2008. eduDrugs.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7161).
3 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 215206.
4 Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.
5 ClinicalTrials.gov (NCT00941304) Study of BEMA Buprenorphine in the Treatment of Dental Pain. U.S. National Institutes of Health.
6 Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors. . The Journal of Headache and Pain 201314(Suppl 1):P75.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 40).
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
9 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 012102.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7191).
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 134).
15 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 45).
16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7596).
17 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
18 Clinical pipeline report, company report or official report of Intelgenx.
19 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 54).
20 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021926.
21 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
22 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216386.
23 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 60).
24 ClinicalTrials.gov (NCT04294147) A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist. U.S. National Institutes of Health.
25 ClinicalTrials.gov (NCT01217775) Intranasal PH80 Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder. U.S. National Institutes of Health.
26 ClinicalTrials.gov (NCT01940315) Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B. U.S. National Institutes of Health.
27 ClinicalTrials.gov (NCT03303105) Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine. U.S. National Institutes of Health.
28 ClinicalTrials.gov (NCT01482949) A Rollover Protocol for Subjects Previously Treated With AGS-003. U.S. National Institutes of Health.
29 ClinicalTrials.gov (NCT02275117) A Multicenter Assessment of ALD403 in Chronic Migraine. U.S. National Institutes of Health.
30 ClinicalTrials.gov (NCT02174861) A Study to Assess the Long-term Safety and Efficacy of AMG 334 in Chronic Migraine Prevention.. U.S. National Institutes of Health.
31 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3380).
32 ClinicalTrials.gov (NCT00751803) BI 44370 TA in Acute Migraine Attack. U.S. National Institutes of Health.
33 ClinicalTrials.gov (NCT00804973) Study in Subjects With Acute Migraines Headaches.. U.S. National Institutes of Health.
34 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 20).
35 ClinicalTrials.gov (NCT00712725) MK3207 for Treatment of Acute Migraines (3207-005). U.S. National Institutes of Health.
36 ClinicalTrials.gov (NCT00920686) Study of NXN 188 for the Treatment of Migraine With Aura. U.S. National Institutes of Health.
37 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 702).
38 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4311).
39 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 703).
40 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039038)
41 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8424).
42 Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. Cephalalgia. 2013 Dec 23;34(7):483-492.
43 ClinicalTrials.gov (NCT01117233) Study In Healthy Adult Volunteers To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429. U.S. National Institutes of Health.
44 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
45 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 120).
46 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002927)
47 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027219)
48 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009029)
49 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 110).
50 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2114).
51 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4208).
52 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005786)
53 ClinicalTrials.gov (NCT01184508) A Study in Migraine Prevention. U.S. National Institutes of Health.
54 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013927)
55 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000706)
56 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008400)
57 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003531)
58 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013923)
59 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010348)
60 Pharmacologic therapeutics for cardiac reperfusion injury. Expert Opin Emerg Drugs. 2007 Sep;12(3):367-88.
61 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 39).
62 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023507)
63 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008398)
64 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007062)
65 Vasostabilizing effect of Dotarizine (Ca(2+)-channel blocker) on cerebrovascular reactivity in rabbits. Neurol Res. 2000 Mar;22(2):229-32.
66 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 15).
67 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015556)
68 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022464)
69 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3228).
70 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019089)
71 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023937)
72 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
73 Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan... J Med Chem. 2008 Aug 28;51(16):4858-61.
74 ALPK1 missense pathogenic variant in five families leads to ROSAH syndrome, an ocular multisystem autosomal dominant disorder. Genet Med. 2019 Sep;21(9):2103-2115. doi: 10.1038/s41436-019-0476-3. Epub 2019 Apr 10.